Business
Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion
Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion.
About this update from Odyssey Health Inc.
[{"type":"text","content":"\n IRVINE, CA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the \"Company\" or \"Odyssey\"), a medical company focused on developing unique, life-saving medical products, today announced successful completion of their clinical trial site initiation visit and the start of subject screening and enrollment. The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally. Odyssey’s Phase 1 clinical trial status can be viewed at www.clinicaltrials.gov.  “We are so excited to start enrollment for our human trials and establish a strong safety profile following PRV-002 nasal application. These studies will look at pharmacokinetics and drug tolerability at 3 dosage strengths. The most tolerated dose will be used in the subsequent trials to determine efficacy,” commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.   Odyssey screening and enrollment of subjects coincides with the completion of their Phase 1 clinical batch of PRV-002. The spray dried material has been filled in its unique breath-propelled nasal applicator and is being shipped this week to the trial site in preparation for first cohort dosing. Each device is uniquely labeled by the manufacturer to comply with the double-blinded nature of the study. “We have a long history of managing successful Phase 1 clinical trials. We are excited to be enrolling subjects and look forward to administering PRV-002 and identifying a safe drug dosage based on tolerability and pharmacokinetics. We feel Odyssey’s unique breath-propelled drug-device combination will promote enrollment while the community need for a concussion treatment should enhance compliance. Concussion is an unmet need that needs to see an effective treatment get approved.” stated, Philip Ryan, MD, Principal Investigator at Nucleus Network, Inc. About Odyssey Group International, Inc.Odyssey Group International, Inc. (OTC:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring ass...